Intensity Therapeutics

Update in progress

INTS (NasdaqCM)

Intensity Therapeutics, Inc. is a late‑stage clinical biotechnology company focused on treating the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead candidate, INT230‑6, is in Phase 3 for soft tissue sarcoma and in Phase 2 for neoadjuvant and metastatic triple‑negative breast cancer. Founded in 2012, it is headquartered in Shelton, Connecticut.